Loading
Everything in development, the open problems and what is being done about them, the roadmaps, and what changed on this record.
What is in development for Myelodysplastic syndromes / neoplasms (MDS), drawn from the whole corpus: 44 items. Drugs are grouped by the most advanced trial phase they have reached anywhere; approved treatments sit under standard of care. Technologies are the methods being tested for this cancer, trials are the studies recorded here, and ideas are proposals not yet in a trial.
No drug has beaten azacitidine in higher-risk MDS.
TP53-mutant and complex-karyotype disease: median survival about a year even after transplant.
Clonal cytopenia of undetermined significance (CCUS): who to watch, who to treat.
Post-HMA failure has no standard.
Dated changes read from the records linked to this cancer: approvals, regulatory steps, reported trials, guideline versions and milestones. Newest first; no date is inferred.
On EdgeAll 29 changes by month →When this page itself was last checked or edited.
Lower-risk MDS transfusion-dependent anaemia
Preparative regimen for allogeneic HSCT in AML/MDS with fludarabine
Venetoclax added to azacitidine did not significantly improve overall survival in untreated higher-risk myelodysplastic syndromes.
Low- to intermediate-1-risk MDS with transfusion-dependent anaemia after ESA failure
IMerge: telomerase inhibitor achieves durable transfusion independence after ESA failure.